TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Keymed Biosciences, Inc. ( (HK:2162) ) has issued an update.
Keymed Biosciences Inc. has announced a board meeting scheduled for August 26, 2025, to review and approve the interim financial results for the first half of the year and consider the payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial health and potential shareholder returns, impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:2162) stock is a Buy with a HK$60.93 price target. To see the full list of analyst forecasts on Keymed Biosciences, Inc. stock, see the HK:2162 Stock Forecast page.
More about Keymed Biosciences, Inc.
Keymed Biosciences Inc. is a company incorporated in the Cayman Islands, operating in the biotechnology industry. It focuses on the development of innovative medical solutions and products, serving various healthcare markets.
Average Trading Volume: 4,346,760
Technical Sentiment Signal: Buy
Current Market Cap: HK$18.63B
For a thorough assessment of 2162 stock, go to TipRanks’ Stock Analysis page.